Active Implantable Medical Devices Market Expansion to be Persistent During 2018 – 2026

Active Implantable Medical Devices Market
Expansion to be Persistent During 2018 – 2026
Active Implantable Medical Devices Market by Product Type (Pacemaker,
Implantable Cardioverter Defibrillator, Cardiac Resynchronization Therapy
Devices, Neurostimulator, Drug Infusion Pump, Implantable Loop Recorder,
Cochlear Implant, and others), and by Region - Global Forecast to 2025
Active implantable medical devices such as cardiac pacemaker systems, cochlear implants, implantable
infusion pumps, cardiac resynchronization therapy devices aid in improving patient’s health and
outcome of the medical treatment. Active implantable medical devices are prosthetic devices, which
provide support in functioning of organs. These devices come under Class II and some under Class III
devices in the U.S. FDA medical devices listing and are subject to stringent regulations as they pose
surgical risks during placement, bruising at surgical site, pain, and high risks due to implant failure. The
active implantable medical devices market is dominated by few leading players such as Medtronic Plc.,
Abbott Laboratories, Boston Scientific Corporation, and Cochlear Ltd. accounting for over 70% of the
market share. Click To Read More On Active Implantable Medical Devices Market.
Market Dynamics
Advancements in technology such as magnetic resonance imaging (MRI) compatible pacemakers and
growing support in favor of use of such devices in cardiovascular and chronic pain diseases is expected
to boost growth of the active implantable medical devices market. For instance, in November 2017,
American Heart Association (AHA), the American College of Cardiology (ACC), and the Heart
Rhythm Society (HRS) approved the use of subcutaneous implantable cardioverter defibrillator, (SICD), for the treatment of ventricular arrhythmias and to prevent cardiac arrest. Major manufacturers in
the market are focusing on collaborations and mergers and acquisitions and are increasingly investing
in research and development of implantable devices. For instance, merger of Sorin Group and
Cyberonics to form LivaNova Plc in 2015. Furthermore, effectiveness of these devices in improving
medical outcomes of cardiovascular and chronic pain diseases, absence of effective alternatives to these
devices and continuous product launches is expected to fuel growth of the market.
The global active implantable medical devices market was valued at US$ 16,721.2 million in 2016 and
is expected to witness a robust CAGR of 5.4% over the forecast period (2017–2025).
Advancements in technology in the product space and new product launches is expected to boost
growth of the active implantable medical devices market
Leading players in the market are focusing on development and launching of new products in order to
remain competitive in the market and retain their market share. Initially, these devices were large in
size, however, miniaturization of pacemakers and ICDs has simplified the implantation procedure and
miniaturization of the products reflects the continuous innovation in the products. This is expected to
fuel demand for such products, in turn reflecting growth of the market. For instance, Medtronic’s first
leadless pacemaker Micra TPS was approved by the U.S. Food & Drug Administration in 2016 and is
known to be the smallest pacemaker. Other innovations such as cardiac contractility modulation, and
wireless pacing are expected to positively impact growth of the active implantable medical devices
market. Implantable continuous glucose monitoring (Sensonic’s Eversense CGM with implantable
sensor, which lasts up to 90 days), and implantable infusion pumps are also expected to propel market
growth. Introduction of wireless technology and mobile connectivity has further led to increased
functions and effectiveness of these devices.
Competitive Analysis
Some major players operating in the active implantable medical devices market are Cochlear Limited,
Boston Scientific Corporation, Medtronic Plc, LivaNova Plc, Abbott Laboratories, Sonova Holding
AG, William Demant holding A/S, Nurotron Biotechnology Co., Ltd., and Med-EL.
Ask For Sample Copy Of This Business Research Report :
https://www.coherentmarketinsights.com/insight/request-sample/1126
Rising prevalence of cardiovascular, chronic pain diseases, and hearing disorders is expected to
boost growth of the active implantable medical devices market over the forecast period
Increasing global prevalence of cardiovascular system diseases, chronic pain diseases, and associated
co morbidities is expected to have a positive impact on the growth of the market. According to the
World Health Organization (WHO), around 17 million people die annually from cardiovascular
diseases. According to the Centers for Disease Control and Prevention (CDC), 2017, 2.7 to 6.1 million
people in the U.S. are suffering from atrial fibrillation, which is the most common type of heart
arrhythmia. Prevalence of neurological disorders such as Parkinson’s disease, epilepsy, essential
tremors, and dystopia is reported to be high in developed and emerging economies such as India. For
instance, around 50,000 people are diagnosed with Parkinson’s disease, annually, in the U.S. according
to National Institute of Health (NIH), 2013 data. Neurostimulation is effective in the treatment of these
neurological diseases, which is expected to support growth of implantable medical devices market over
the forecast period.
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready
syndicated research reports, custom market analysis, consulting services, and competitive analysis
through various recommendations related to emerging market trends, technologies, and potential
absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1–206–701–6702
Email: [email protected]

Active implantable medical devices such as cardiac pacemaker systems, cochlear implants, implantable infusion pumps, cardiac resynchronization therapy devices aid in improving patient’s health and outcome of the medical treatment.